ALLO R&D to Revenue
Allogene Therapeutics Inc · R&D to Revenue
ALLO R&D to Revenue
Latest reported662.09%period ending
ALLO Quarterly R&D/Revenue (0.00% → 662.09%)
Latest values, visible window
High-resolution chart · PNG
ALLO r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 662.0905% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 237,540.9091% | |
| -124,229.5455% | |
| 208,986.3636% | |
| 281,990.9091% | |
| 267,460% | |
| 160,465.9574% | |
| 129,879.5918% | |
| 66,477.907% | |
| 98,616.3934% | |
| 105,849.0196% | |
| 119,836.7347% | |
| 118,840.9091% | |
| 143.9119% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |